Mineralys Therapeutics Inc. Common Stock (MLYS)

About MLYS

Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep a…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

76

Website

mineralystx.com/

Fundamentals

1-day range

$26.7$27.75

Market cap

$2.23B

P/E (trailing)

—

P/E (forward)

-10.78

EPS (trailing)

$-2.06

Dividend yield

—

Beta

0.61

Avg. volume

1.40M

Forecasts

8 analyst ratings

Mineralys Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• MLYS

  Mineralys Therapeutics Inc. Common Stock

  $25.59

  ▼ 1.61%
  Market cap $2.23BP/E —
  $14.94$47.65
• URGN

  UroGen Pharma Ltd. Ordinary Shares

  $43.61

  ▼ 4.15%
  Market cap $2.22BP/E —
  $15.86$50.81
• SLS

  SELLAS Life Sciences Group Inc. Common Stock

  $13.17

  ▼ 13.45%
  Market cap $2.18BP/E —
  $1.39$15.88
• BHVN

  Biohaven Ltd. Common Shares

  $15.42

  ▼ 4.37%
  Market cap $2.17BP/E —
  $7.48$18.57
• VERA

  Vera Therapeutics Inc. Class A Common Stock

  $34.19

  ▼ 1.18%
  Market cap $2.30BP/E —
  $21.2$56.05
• VRDN

  Viridian Therapeutics Inc. Common Stock

  $23.09

  ▼ 3.31%
  Market cap $2.32BP/E —
  $13.18$34.29
• NUVB

  Nuvation Bio Inc. Class A Common Stock

  $6.67

  ▼ 4.65%
  Market cap $2.13BP/E —
  $2.87$9.75

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• THQ Offers High-Yield Income From Healthcare Stocks (Rating Upgrade)
  SeekingAlpha · 8/27/2026
• Mineralys Therapeutics, Inc. (MLYS) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/12/2026
• Mineralys Therapeutics Q2 EPS $(2.85) Misses $(0.55) Estimate
  benzinga · 8/11/2026

• Eric Warren · August 21, 2026 · Option Exercise

  7.4K @ $13.24
• Eric Warren · August 21, 2026 · Sale

  7.4K @ $25.98
• James J. Ferguson III · August 10, 2026 · Grant

  135.0K
• James J. Ferguson III · August 10, 2026 · Grant

  102.4K
• David Malcom Rodman · August 10, 2026 · Option Exercise

  2.2K @ $16
• David Malcom Rodman · August 10, 2026 · Sale

  2.2K @ $27.09
• Eric Warren · July 21, 2026 · Option Exercise

  7.4K @ $13.24
• Eric Warren · July 21, 2026 · Sale

  7.4K @ $26.87
• David Malcom Rodman · July 17, 2026 · Option Exercise

  416 @ $15.44
• David Malcom Rodman · July 17, 2026 · Sale

  416 @ $26.53
• David Malcom Rodman · July 15, 2026 · Sale

  6.3K @ $26.61
• David Malcom Rodman · July 13, 2026 · Option Exercise

  6.3K @ $1.08
• David Malcom Rodman · July 13, 2026 · Option Exercise

  4.2K @ $14.25
• David Malcom Rodman · July 13, 2026 · Option Exercise

  3.5K @ $10.2
• David Malcom Rodman · July 13, 2026 · Sale

  14.1K @ $27.58

Institutional Ownership

March 31, 2026

Total shares held

96.46M

Total value held

$2.56B

Institutional holders

210